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Abstract
Background: The epidemiological importance of varicella and zoster and the availability of an
efficacious and safe vaccine have led to an important international debate regarding the suitability
of mass vaccination. The objective of the study was to describe the epidemiology of varicella and
zoster in Italy and to determine whether there have been changes with respect to observations
provided by an analogous study conducted 8 years ago, in order to define the most appropriate
vaccination strategy.
Methods: A number of data sources were evaluated, a cross-sectional population-based
seroprevalence study was conducted on samples collected in 2004, and the results were compared
with data obtained in 1996.
Results: The data from active and passive surveillance systems confirm that varicella is a
widespread infectious disease which mainly affects children. VZV seroprevalence did not
substantially differ from that found in the previous study. The sero-epidemiological profile in Italy
is different from that in other European countries. In particular, the percentage of susceptible
adolescents is at least nearly twice as high as in other European countries and in the age group 20–
39 yrs, approximately 9% of individuals are susceptible to VZV.
Conclusion: The results of this study can contribute to evaluating the options for varicella
vaccination. It is possible that in a few years, in all Italian Regions, there will exist the conditions
necessary for implementing a mass vaccination campaign and that the large-scale availability of
MMRV tetravalent vaccines will facilitate mass vaccination.
Background
Varicella is a ubiquitous highly contagious infectious dis-
ease caused by the varicella zoster virus (VZV) [1]. After
primary infection, VZV tipically remains latent in the dor-
sal root ganglia and after many years results in zoster [2].
Approximately 10–20% of adults in the course of their
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acterized by unilateral radicular pain and a vescicular
eruption generally limited to a dermatome. Of the zoster-
related complications, the most common is post-herpetic
neuralgia, which can considerably worsen an individual's
quality of life [3]. The development of zoster seems to be
associated with advanced age and decreased immune
response (in particular the cell-mediated response) [4].
The epidemiological importance of varicella and zoster
and the availability of an efficacious and safe vaccine [5,6]
have led to an important international debate regarding
the suitability of mass vaccination. At the European level,
the European Working Group on Varicella (EuroVar) has
recently recommended that routine varicella vaccination
be performed for healthy children 12–18 months of age
and for all susceptible children before 13 years of age, in
addition to catch up for older children and adults who are
anamnestically negative for the infection and at high risk
of transmission, exposure, or complications. However,
mass vaccination is recommended only for countries
where high vaccination coverage can be rapidly achieved
and maintained [7]. This is to avoid problems that have
occurred in the past with measles, mumps, and rubella; in
particular, the sub-optimal vaccination coverage has
reduced, but not stopped, viral circulation, creating a pool
of susceptible individuals among older children and
adults [8].
In Italy, although varicella is subject to statutory notifica-
tion, it is often underreported. Thus the data provided by
routine notification need to be validated and integrated
with data from other sources, such as sentinel surveillance
systems or sero-epidemiological investigations. This is
especially important when evaluating whether or not to
perform mass vaccination or assessing the impact of vac-
cination campaigns that have already been implemented.
The objective of the present study was to describe the epi-
demiology of varicella and zoster in Italy using a number
of data sources and to determine whether there have been
changes with respect to observations provided by an anal-
ogous study conducted 8 years ago, in order to define the
most appropriate vaccination strategy.
Methods
Incidence data
In Italy, varicella is subject to mandatory notification, and
all reported cases are recorded by Italy's National Census
Bureau (ISTAT). For zoster, notification is not mandatory;
thus no national-level data are available.
We analysed ISTAT data on cases of varicella for the period
1991–2004. We determined the trend in crude incidence
per 100,000 inhabitants, using as reference the Italian
population included in national censuses (for the years
1991 and 2001) or estimates provided by ISTAT (for the
remaining years). Moreover, we calculated the trend in
incidence for the periods 1991–1995, 1996–2000, and
2001–2004, by age class: 0–14, 15–24, 25–64, and ≥65
years. For each of these periods, the trend in incidence by
geographic area was also evaluated (northern Italy, central
Italy, and southern Italy and the islands).
Evaluation of other databases
To conduct a more in-depth epidemiological evaluation,
we analysed data from other databases with information
on varicella and zoster. With specific regard to varicella,
we considered the incidence data from Italy's Paediatric
Sentinel Surveillance System of Vaccine-Preventable Dis-
eases (SPES) for the years 2000–2005. Surveillance con-
sists of collecting data from a network of paediatricians
located throughout Italy. In the period considered,
approximately 320–470 paediatricians participated, with
a national coverage of approximately 2.5–5% for persons
0–14 years of age.
We also examined the National Hospital Discharge Data-
base, created in 1994, which collects information on all
hospitalizations recorded in Italy [9]. For the analysis of
the data from this latter database, which is freely available
from the web site of the national Ministry of Health, we
considered the main reason for hospitalization, which is
codified using ICD9-CM (code 052 for varicella and code
053 for zoster). The analysis was performed on data for
the period 2000–2003.
Finally, we reviewed data on mortality due to varicella and
zoster for the years 1991–2002, provided by ISTAT.
Seroprevalence study
A national cross-sectional population-based seropreva-
lence study of varicella antibodies was conducted in com-
pliance with the Helsinki Declaration and with the Law
Decree n. 196/2003, article 24 (Code for the protection of
personal data). In the period from January 2003 to Octo-
ber 2004, blood samples were collected from at least one
reference laboratory in eighteen out of Italy's 20 Regions,
so that the sample would be geographically representa-
tive. The samples had been taken for diagnostic purposes
or routine ascertainment and had been frozen at -20°C
until use and were analyzed by the same national refer-
ence laboratory (University of Salento, Lecce).
For each person from whom blood was collected, the pur-
pose of the study was explained and oral informed con-
sent for using the sample for the study was obtained.
Specimens were collected anonymously and only age, sex
and date of sampling were recorded. We excluded from
the study immunocompromised patients, those who had
received a blood transfusion in the previous 6 months,Page 2 of 9
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reference laboratory was asked to collect 6 samples for
each year of age in the 0–20-year age group, 10 samples
for each 5-year range in the 21–40-year age group, and a
total of 10 samples for the 41–50-year age group. The
samples had to be equally representative of males and
females. A total of 3,094 serum samples were collected.
Varicella antibodies were quantified using an immunoen-
zyme micro-method (Enzygnost anti-VZV-virus/IgG,
Dade Behring GmbH), which has a high sensitivity and
specificity (respectively, 99.3% and 100%).
The following criteria were applied for the qualitative
evaluation:
- IgG negative sample ΔE < 0.100 (cut-off)
- IgG positive sample ΔE > 0.200
- Equivocal IgG sample 0.100≤ΔE≤0.200
The equivocal samples were retested: if the result was con-
firmed, the sample was classified as "equivocal". The IgG
positive samples were quantitatively evaluated using the
following formula: Log10 mIU/ml = α × ΔEβ, where α andβ represent lot-dependent constants. Antibody activity
was expressed in mIU/ml, in accordance with the interna-
tional standard for varicella-zoster immunoglobulin of
the World Health Organization; the cut-off for the test was
50 mIU/ml, equivalent to a ΔE of 0.100.
Statistical analysis
Direct standardized incidence rates were calculated by
using national 1991 census data as the reference popula-
tion.
Seroprevalence data were summarized as percentages with
95% confidence interval (95%CI) and positive antibody
titres presented as geometric means. Differences among
percentages of seropositive subjects were assessed by the
chi-square test, while differences among geometric titres
were assessed by Student's t test of logarithmically trans-
formed values.
Data were also analysed by gender and geographical area,
and were then compared with results obtained from a
seroprevalence study conducted with the same test
method and cut-off in 1996 [10].
A multiple logistic regression model was used to deter-
mine the relationship between antibody titres (positive
versus negative) and a set of explanatory variables. The
following variables were included in the model: sex, age
group, geographical area and year of sample collection.
The likelihood ratio test was used to compare different
models. Statistical analysis was performed by Stata soft-
ware version 9.2.
Results
Incidence data
Based on the data provided by ISTAT, varicella was con-
firmed to be a disease which each year affects a large pro-
portion of the population (Figure 1). The overall
standardized annual incidence ranged from 164.4 to
244.2 per 100,000 population in the years 1991–2004.
For all three periods considered (1991–1995, 1996–2000
and 2001–2004), it clearly emerged that varicella mainly
affects children (0–14 years). Moreover, in this age group,
the reported incidence significantly increased, from 996
per 100,000 population in 1991–1995 to 1,164 in 2001–
2004 (p < 0.01), whereas in the other age groups it
decreased (significantly in the age group 15–24 years, p <
0.01).
When comparing persons 0–14 years of age to those 15
years of age and older, there was a significant increase (p
< 0.01) in the percentage of cases represented by the
younger age class, from 81.4% in 1991–1995 to 85.2% in
1996–2000 and 88.4% in 2001–2004.
The analysis by geographic area showed that, although the
trend in incidence was similar for the three areas, there
was a clear north-south gradient, with the highest inci-
dence consistently found for northern Italy, followed by
central and then southern Italy (Figure 1).
Evaluation of other databases
In the period 2000–2005, 92,288 cases of varicella were
reported to SPES, with the annual incidence ranging from
4,053 per 100,000 children (0–14 years) (2005) to 6,655
per 100,000 children (2004). In general, there was a trend
of decrease in incidence from northern to southern Italy
(Table 1).
According to the National Hospital Discharge Database,
in the period 2000–2003, there was an annual mean of
1,575 hospitalisations for varicella (1,521 hospitalisa-
tions and 54 day-hospital admissions). The mean dura-
tion of stay was 5.3 days. For zoster, in the same period,
there was an annual mean of 5,250 hospitalisations
(4,711 hospitalisations and 539 day-hospital admis-
sions). The mean duration of stay was 8.3 days. Of the
total hospital admissions for zoster, 62.1% were for per-
sons greater than 65 years of age.
With regard to mortality, in the period considered (1991–
2002), ISTAT reported 66 deaths for varicella (average of
5.5 deaths per year). In the same period, there were 416Page 3 of 9
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among persons older than 65 years of age.
Seroprevalence study
Overall, 2,367 samples were positive; 675 were negative,
and 52 were equivocal. The seroprevalence followed a typ-
ical trend, with a decreased seroprevalence in the second
year of life, compared to the first year (i.e., when children
are initially passively protected by the mother). Beginning
at 2 years of age, it progressively increased, reaching
32.9%, 67%, 84.6%, and 85.4%, respectively, in the age
classes 2–4, 5–9, 10–14 and 15–19 years. In the age
classes 20–39 and >40 years, the seroprevalence was 91%
and 98.4%, respectively (Figure 2). The trend in seroprev-
alence was similar for males and females, with no statisti-
cally significant difference.
Analyzing data by geographical area (northern, central,
and southern Italy), the trend in seroprevalence was basi-
cally uniform (Figure 3), though there were statistically
significant differences when comparing the data for the
following age classes:
- 5–9 years, northern vs. southern Italy, χ2 = 8.70 (p =
0.003)
- 10–14 years, northern vs. southern Italy, χ2 = 4.49 (p =
0.026)
- 15–19 years, northern vs. central Italy, χ2 = 5.82 (p =
0.016)
- 15–19 years, northern vs. southern Italy, χ2 = 4.68 (p =
0.043)
- ≥ 40 years, northern vs. southern Italy, χ2 = 4.34 (p =
0.037)
However, multivariate analysis showed that the only vari-
able associated with antibody titre is age group.
Varicella in Italy: area specific and national incidence rates/100,000 population, 1991–2004Figure 1
Varicella in Italy: area specific and national incidence rates/100,000 population, 1991–2004.
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Table 1: Varicella in Italy: SPES Survey, incidence/100,000 
children 0–14 yrs, 2000–2005
Year Northern Italy Central Italy Southern Italy Italy
2000 6,034 5,234 4,852 5,340
2001 7,053 5,705 4,576 5,741
2002 5,605 6,168 5,031 5,459
2003 6,865 5,438 4,532 5,635
2004 7,297 6,400 6,120 6,655
2005 3,802 5,462 3,719 4,053Page 4 of 9
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Varicella-zoster virus seroprevalence by age-group and gender in Italy, 2003–2004Figure 2
Varicella-zoster virus seroprevalence by age-group and gender in Italy, 2003–2004.
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Varicella-zoster virus seroprevalence by age-group and geographical area in Italy, 2003–2004Figure 3
Varicella-zoster virus seroprevalence by age-group and geographical area in Italy, 2003–2004.
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BMC Public Health 2008, 8:372 http://www.biomedcentral.com/1471-2458/8/372The GMT showed a trend of decrease in the first year of life
and then a progressive increase in older age classes. This
increase was statistically significant (p < 0.01) when com-
paring a given age class with the successive age class,
except when comparing the 10–14-year age class to the
15–19-year age class, between which the GMT decreased,
though not significantly. There were no significant differ-
ences when comparing males to females.
Comparison of seroprevalence data from 1996 and 2004
The proportion of seropositive persons did not substan-
tially differ from that reported in a study conducted using
the same methods on samples collected in 1996–1997
[10]. No changes were detected in any of the age-groups,
and the same trend was evident for both males and
females (Figure 4).
Discussion
Active and passive surveillance systems are extremely
important for the evaluation of the epidemiological
impact of an infectious disease. However, data collected
through these systems have both strengths and weak-
nesses. For example, the national routine notification sys-
tem adopted in Italy, being mandatory, is useful to
describe the epidemiology of a specific infectious disease
and allows the evaluation of historical temporal trends
but is certainly affected by undernotification and under-
diagnosis. Sentinel surveillance systems, such as SPES,
being active surveillance systems, are certainly more pre-
cise, but their implementation is difficult and expensive.
On the other hand, hospital discharge databases have
poor sensitivity and a limited potential for clinical inter-
pretation; however, they allow the evaluation of the more
clinically serious infections. For all these reasons it is
important, when possible, to evaluate different data
sources to study the epidemiology of an infectious dis-
ease. The data from the statutory notification system for
the years 1991–2004 confirm that varicella is a wide-
spread infectious disease which mainly affects children.
However, this system greatly suffers from underreporting.
For example, in the period 2000–2004, the estimated inci-
dence in the 0–14-year age class ranged from 1021.93 to
1368.31 per 100,000 population, whereas the incidence
estimated based on data collected by SPES ranged from
5,340 to 6,655 per 100,000 population, which is consist-
ent with the incidence of 6,200 per 100,000 population
reported in a previous study and based on data provided
by volunteer paediatricians [11]. These findings suggest
that data collected by healthcare professionals on a volun-
tary basis may be more accurate than those collected by
statutory notification systems. Based on the data provided
by the statutory notification system and SPES, it can be
Comparison between varicella-zoster virus seroprevalence by age-group in Italy, 1996–1997 and 2003–2004Figure 4
Comparison between varicella-zoster virus seroprevalence by age-group in Italy, 1996–1997 and 2003–2004.
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cases of varicella each year [12] which correspond to a
birth cohort.
The percentage of cases represented by persons ≥15 years
of age progressively decreased, from 18% in the period
1991–1995 to 10.7% in the years 2001–2004. This seems
to represent an inversion of the trend reported in a previ-
ous Italian study, in which the percentage of cases repre-
sented by persons ≥15 years of age progressively increased
in the period 1961–1996 [10]; similar trends of increase
have also been reported by other studies outside Italy
[13]. Instead, the geographic differences in incidence
(comparing northern, central, and southern Italy) were
confirmed.
The seroprevalence study confirmed that in Italy VZV
infection is predominantly a paediatric disease, and the
results did not substantially differ from those of study
conducted using the same methods on samples collected
in 1996–1997 [10]. The trend in seroprevalence was sim-
ilar for males and females and for geographical areas.
Multivariate analysis showed that the only variable associ-
ated with antibody titre is age group. This is strongly sug-
gestive that the epidemiology of VZV does not vary
geographically in Italy. As a matter of fact, regional differ-
ences were particularly pronounced using the incidence
data but much less so with the antibody prevalence
results. These differences may be explained by the high
degree of undernotification in southern Italy [12]. Also
the higher seroprevalence registered in northern Italy may
be related to the higher spreading of VZV in northern
regions where a large part of the population lives in large
urban and industrial settings.
The GMT showed a trend of progressive increase, indicat-
ing, as found in 1996–97, the existence of natural boost-
ers deriving from the persistent circulation of the
etiological agent. Nonetheless, it should be stressed that,
for both genders, approximately 15% of adolescents and
9% of persons in the 20–39-year age class are susceptible.
In designing the sero-prevalence study, the representative-
ness of the sample was pursued following indications pro-
vided by the European Project for the Sero-
epidemiological Surveillance of Vaccine-preventable dis-
eases. Although the samples from very young subjects
could have been collected from children affected by
health problems, the inclusion and exclusion criteria
adopted in this study should have allowed to exclude
these children, thus avoiding an overestimation of sero-
prevalence.
This study shows that the sero-epidemiological profile in
Italy is different from that in other European countries. In
particular, in Italy, the percentage of persons who are sus-
ceptible is at least nearly twice as high as the percentages
in the other countries participating in the European
Seroepidemiology Network (ESEN) [14-17]. This con-
firms that there are important differences in the age of dis-
ease acquisition, and it is consistent with the finding that,
among the ESEN countries, Italy has the lowest reproduc-
tion number (R0) and force of infection (calculated using
seroepidemiological data from 1996–97) [18]. Moreover,
in Italy, the high percentage of persons who are suscepti-
ble in the 20–39-year age class indicates that there is a
concrete risk for VZV infection for pregnant women [19].
The results of this study can contribute to evaluating the
options for varicella vaccination. As mentioned, before
evaluating these options, it is necessary to have complete
and updated epidemiological data, the acquisition of
which entails not only performing seroepidemiological
investigations but also creating or implementing passive
or active surveillance systems for varicella and zoster. In
Italy, reliable data for the 0–14-year age class are available
from SPES, whereas the routine notification system suf-
fers, as mentioned, from underreporting.
With regard to the actual vaccination options, mass vacci-
nation in infancy (12–18 months of age), together with
the vaccination of all susceptible persons by 13 years of
age, would substantially decrease the spread of the disease
and would protect more persons at high risk of complica-
tions [7]. However, it would be necessary to achieve high
vaccination coverage rapidly, so as to avoid an increase in
the mean age of acquisition of the infection and thus in
the risk of complications.
There is a theoretical negative impact of mass vaccination
in terms of increasing the incidence of zoster. In particu-
lar, given that exposure to VZV boosts natural immunity,
the decreased circulation resulting from mass vaccination
could potentially result in an increased number of cases of
zoster [20] in first decades of a universal mass vaccination
program.
Although in Italy there are no complete or updated epide-
miological data on zoster, it has been estimated that in
persons greater than 14 years of age there are approxi-
mately 200,000 cases of zoster, and 42,000 of post-her-
petic neuralgia each year [21] and this risk of a further
increase following mass vaccination needs to be carefully
considered. However, data currently available do not sup-
port this hypothesis [22]. Moreover, the possibility of
using a vaccine with a high antigen titer for preventing
zoster in adults is being considered [23].
An alternative option would be that of vaccinating only
susceptible adolescents and adults, which does notPage 7 of 9
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Although this type of intervention would have a limited
impact on the epidemiology of the infection, it would
contribute to decreasing the incidence among persons at
the greatest risk of complications. The analysis of the data
from the National Hospital-Discharge Database showed
that a small proportion of persons with varicella are hos-
pitalised; in the period 2000–2003 (the years for which
data were available), a mean of 1,575 hospitals admis-
sions had varicella reported as the main diagnosis. How-
ever, considering that approximately one third of these
cases occur among people older than 14 years, and that
these cases could be prevented by the selective vaccination
of adolescents and adults, this option merits considera-
tion.
Conclusion
Italy's 2005–2007 National Vaccination Plan [24] recom-
mends vaccinating persons at high risk of complications,
susceptible adolescents, healthcare workers, and the staff
of day-care centres and schools with small children. Mass
vaccination is only recommended in regions where a vac-
cination coverage of greater than 80% for MMR can be
achieved. To date, national-level mass vaccination has not
been performed, and the vaccination strategy varies
greatly among Italy's 20 Regions: some Regions have
already begun or plan to begin mass vaccination, whereas
others have decided to vaccinate only susceptible adoles-
cents, and still others have not decided on any type of
intervention. The current strategy is quite different from
that reported in the previous study, where the use of vari-
cella vaccine was recommended only for individuals at
risk, and the possibility of implementing vaccine cam-
paigns targeting susceptible women and healthcare per-
sonnel was being considered.
A cluster sampling survey conducted in 2003 revealed a
national MMR vaccination coverage of 77%, in children
aged 13–24 months of age [25] and routine coverage data
provided by Regions to the Italian Ministry of Health in
2004 showed an MMR vaccination coverage of 85.5%. It
is therefore possible that in a few years, in all Italian
Regions, there will exist the conditions necessary for
implementing a mass vaccination campaign and that the
large-scale availability of MMRV tetravalent vaccines in
the near future will facilitate mass vaccination.
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